



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(s): BARTHOLOMAUS et al.
SERIAL NO.: 10/718,112 ART UNIT:
FILING DATE: 11/20/03 EXAMINER:
TITLE: ABUSE-PROOFED DOSAGE FORM
ATTORNEY
DOCKET NO.: 785-011574-US (PAR)

Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT
(37 C.F.R. §1.97(b)(3))

Sir:

This information disclosure statement is being filed before the mailing of a first Office Action on the merits.

The following information is being disclosed to the Patent and Trademark Office as information that may be material to the examination of the above-identified patent application. Applicants' Attorney is aware of the following references:

US 4,070,494
WO 95/20947
WO 03/015531
US 2003/0064099
US 4,765,989
US 4,612,008
US 4,783,337
WO 98/20073
DE 197 53 534
DE 198 00 698
EP 0 820 698
DE 198 22 979

DE 43 09 528
EP 0 980 894
EP 0 780 369
EP 0 693 475

Pharmazeutische Biologie Drogen und ihre Inhaltsstoffe
(pp. 82-92)

Coated Pharmaceutical Dosage Forms (pp. 1-10)


2.9 Methoden der pharmazeutischen Technologie (pp. 143-144)

Copies of these references are enclosed together with a Form PTO-1449.

The filing of this Statement is not to be construed as a representation that a search has been made regarding the claimed invention (37 C.F.R. §1.97(g)) or that no other possible material information exists. In addition, the filing of this Information Disclosure Statement is not to be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability (37 C.F.R. §1.97(h)).

The Commissioner is hereby authorized to charge payment for any fees associated with this communication or credit any over payment to Deposit Account No. 16-1350.

Respectfully submitted,


Geza S. Ziegler, Jr.
Reg. No. 44,004

24 Feb 2004
Date

PERMAN & GREEN, LLP
425 Post Road
Fairfield, CT 068424
Customer No. 2512

INFORMATION DISCLOSURE CITATION FORM FOR PATENT APPLICATION (Substitute) <small>MAR 01 2004 FORM PTO-1449</small>		Docket No.: 785-011574-US (PAR)		Serial No.: 10/718,112		
		Applicant(s): BARTHOLOMAUS et al.				
		Filing Date: 11/20/03		Group:		
U.S. PATENTS						
	Patent Number	Issue Date	Name	Class	Sub-class	Filing date
	4,070,494 4,612,008 4,765,989 4,783,337	1/24/78 9/16/86 8/23/88 11/8/88	Hoffmeister et al. Wong et al. Wong et al. Wong et al.	424 604 424 424	2 892 473 468	
U.S. PATENT PUBLICATIONS						
Initials	Publication No.	Pub. Date	Name	Class	Sub-class	Filing Date
	2003/0064099	4/3/03	Oshlack et al.	424	465	
FOREIGN PATENT DOCUMENTS						
Initials	Document Number	Date	Country	Name		Translation? Yes/No/n/a
	WO 95/20947 WO 03/015531 WO 98/20073 DE 19753534 DE 19800698 EP 0820698 DE 19822979 DE 4309528 EP 0980894 EP 0693475 EP 0780369	10.08.95 27.02.03 14.05.98 03.12.97 10.01.98 28.01.98 25.05.98 24.03.93 23.02.00 24.01.96 25.06.97	PCT PCT PCT Germany Germany EPO Germany Germany Germany EPO EPO	Rhonepoulenc Rorer Limited Gruber, Thomas Novamont S.P.A. Bayer AG Bayer AG Wolff Walsrode AG Kalle Nalo GmbH & Co. Metzger, Wolfgang Mitsui Chemicals, Inc. Grunenthal GmbH Grunenthal GmbH		N/A N/A N/A No No No No No N/A No No
OTHER DOCUMENTS (Title, Author, Date, Pages, Etc., if known)						
	Pharmazeutische Biologie Drogen und ihre Inhaltsstoffe, Professor Dr. Hildebert Wagner, Munchen, 1982, Pages 82-92.					
	2.9 Methoden der pharmazeutischen Technologie, pages 143-144.					
	Coated Pharmaceutical Dosage Forms, K.H. Bauer, et al., CRC Press, 1998, pages 1-10.					
Examiner's Signature:				Date Considered:		
Initial if reference was considered, whether or not citation is in conformance with MPEP. Mark through citation if not considered. Include a copy of this citation form with your next correspondence to the Applicant(s).						